New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

9

Roche abandons AKT prostate cancer asset

Roche is dropping its investigational AKT inhibitor ipatasertib, which was being assessed in a Phase III trial for castration-resistant prostate cancer, the company revealed Thursday in its 2022 full-year financial report.